Click here to sign in with or
Forget Password?
Learn more
share this!
1
5
Share
Email
December 7, 2022
by Babraham Institute
Researchers from the Liston lab, at the Babraham Institute, have recently published details about a preventative therapeutic for diabetes in mice. The team has been able to prevent diabetes in mice by manipulating signaling pathways in pancreatic cells to prevent stress-induced cell death. The treatment targets a pathway common to both major types of diabetes and therefore could have huge therapeutic potential once translated into a clinical treatment.
Dr. Kailsah Singh, former research fellow in the Liston lab, described their findings: “Our results show that MANF could prevent the beta cell damage by preventing the inflammation in islets, which is a hallmark of type 1 diabetes.”
For over 35 years there have been failed attempts to prevent type 1 diabetes development. Previous approaches have sought to target the autoimmune nature of the disease, but Dr. Adrian Liston, senior Group Leader in the Immunology research program, wanted to investigate if there was more causing the deterioration in later stages than just the immune response.
The Liston lab sought to understand the role of cell death in the development of diabetes and therefore approached this problem by identifying the pathways that decide whether stressed insulin-producing cells of the pancreas live or die, and therefore determine the development of disease.
Their hope was to find a way to stop this stress-related death, preventing the decline into diabetes without the need to focus solely on the immune system. First, the researchers had to know which pathways would influence the decision of life or death for the beta cell.
In previous research, they were able to identify Manf as a protective protein against stress induced cell death, and Glis3 which sets the level of Manf in the cells. While type 1 and 2 diabetes in patients usually have different causes and different genetics, the GLIS3-MANF pathway is a common feature for both conditions and therefore an attractive target for treatments.
In order to manipulate the Manf pathway, the researchers developed a gene delivery system based on a modified virus known as an AAV gene delivery system. The AAV targets beta cells, and allows these cells to make more of the pro-survival protein Manf, tipping the life-or-death decision in favor of continued survival.
To test their treatment, the researchers treated mice susceptible to spontaneous development of autoimmune diabetes. Treating pre-diabetic mice resulted in a lower rate of diabetes development from 58% to 18%. This research in mice is a key first step in the development of treatments for human patients.
“A key advantage of targeting this particular pathway is the high likelihood that it works in both type 1 and type 2 diabetes,” explains Dr. Adrian Liston.
“In type 2 diabetes, while the initial problem is insulin-insensitivity in the liver, most of the severe complications arise in patients where the beta cells of the pancreas have been chronically stressed by the need to make more and more insulin. By treating early type 2 diabetes with this approach, or a similar one, we have the potential to block progression to the major adverse events in late-stage type 2 diabetes.”
The paper is published in the journal Biomolecules.
Explore further
Facebook
Twitter
Email
Feedback to editors
23 hours ago
0
Dec 6, 2022
0
Dec 6, 2022
0
Dec 6, 2022
0
Dec 5, 2022
0
11 minutes ago
57 minutes ago
1 hour ago
1 hour ago
16 hours ago
16 hours ago
17 hours ago
17 hours ago
17 hours ago
18 hours ago
Aug 31, 2022
Nov 9, 2022
Mar 21, 2016
Feb 3, 2022
Jul 14, 2022
Jun 28, 2022
17 hours ago
23 hours ago
22 hours ago
Dec 8, 2022
Dec 7, 2022
Dec 7, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.